Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689021 | 0.82 | ALDH1A1 (0.57) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL29793691 | 0.81 | MAPT (0.46) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL15490163 | 0.81 | MAPT (0.46) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL16994789 | 0.81 | ALDH1A1 (0.47) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL31565670 | 0.79 | IKBKB (0.49) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL12505382 | 0.79 | GAA (0.54) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15486878 | 0.79 | MAPT (0.44) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL20529167 | 0.77 | CYP2A6 (0.41) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL1003845 | 0.75 | MEN1 (0.53) | ALDH1A1MAPTTSHRSMN1; SMN2MAPK1 | |
| SCHEMBL7596950 | 0.75 | C5AR1 (0.53) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | VIROSTATICS SRL (IT) | 2017-07-20 | — | — | US | disclosed |
| US-9617225-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | VIROSTATICS SRL (IT) | 2014-02-27 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057911-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS | DPYD, ABL1, BRD4 | ALDH1A1 507/4885GAA 3841/4885MAPT 2753/4885 |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | UMPS, DPYD, DUT | ALDH1A1 942/4885GAA 1273/4885MAPT 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.